SE0000597D0 - Novel antibody - Google Patents

Novel antibody

Info

Publication number
SE0000597D0
SE0000597D0 SE0000597A SE0000597A SE0000597D0 SE 0000597 D0 SE0000597 D0 SE 0000597D0 SE 0000597 A SE0000597 A SE 0000597A SE 0000597 A SE0000597 A SE 0000597A SE 0000597 D0 SE0000597 D0 SE 0000597D0
Authority
SE
Sweden
Prior art keywords
target
binds
substance
blocks
tumour cells
Prior art date
Application number
SE0000597A
Other languages
English (en)
Swedish (sv)
Inventor
Thomas N Brodin
Pia J Karlstroem
Bo H K Nilsson
Lennart G Ohlsson
M Jesper Tordsson
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE0000597A priority Critical patent/SE0000597D0/xx
Publication of SE0000597D0 publication Critical patent/SE0000597D0/xx
Priority to US10/182,132 priority patent/US7425623B2/en
Priority to CN01805577A priority patent/CN1406136A/zh
Priority to BR0108609-0A priority patent/BR0108609A/pt
Priority to AU36294/01A priority patent/AU775876B2/en
Priority to HU0300007A priority patent/HUP0300007A3/hu
Priority to PCT/SE2001/000395 priority patent/WO2001062286A1/en
Priority to NZ520523A priority patent/NZ520523A/en
Priority to YU63702A priority patent/YU63702A/sh
Priority to IL15132501A priority patent/IL151325A0/xx
Priority to KR1020027010963A priority patent/KR20020079888A/ko
Priority to RU2002125386/15A priority patent/RU2268068C2/ru
Priority to CA002400661A priority patent/CA2400661A1/en
Priority to EEP200200473A priority patent/EE200200473A/xx
Priority to EP01908551A priority patent/EP1257291A1/en
Priority to MXPA02008315A priority patent/MXPA02008315A/es
Priority to SK1198-2002A priority patent/SK11982002A3/sk
Priority to JP2001561350A priority patent/JP2003523213A/ja
Priority to PL01356386A priority patent/PL356386A1/xx
Priority to ZA200206039A priority patent/ZA200206039B/en
Priority to NO20023670A priority patent/NO20023670L/no
Priority to HK03104939.3A priority patent/HK1052648A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0000597A 2000-02-24 2000-02-24 Novel antibody SE0000597D0 (sv)

Priority Applications (22)

Application Number Priority Date Filing Date Title
SE0000597A SE0000597D0 (sv) 2000-02-24 2000-02-24 Novel antibody
PL01356386A PL356386A1 (en) 2000-02-24 2001-02-23 Novel antibody with specificity for colon cancer
KR1020027010963A KR20020079888A (ko) 2000-02-24 2001-02-23 결장 암에 대해 특이성을 가지는 신규한 항체
CA002400661A CA2400661A1 (en) 2000-02-24 2001-02-23 Novel antibody with specificity for colon cancer
BR0108609-0A BR0108609A (pt) 2000-02-24 2001-02-23 Anticorpo com especificidade pelo câncer de cólon
AU36294/01A AU775876B2 (en) 2000-02-24 2001-02-23 Novel antibody with specificity for colon cancer
HU0300007A HUP0300007A3 (en) 2000-02-24 2001-02-23 Antibody with specificity for colon cancer
PCT/SE2001/000395 WO2001062286A1 (en) 2000-02-24 2001-02-23 Novel antibody with specificity for colon cancer
NZ520523A NZ520523A (en) 2000-02-24 2001-02-23 A binding structure determined by it heavy chain CDR structures which binds to the cell surface of tumour cells
YU63702A YU63702A (sh) 2000-02-24 2001-02-23 Novo antitelo sa specifičnošću za rak debelog creva
IL15132501A IL151325A0 (en) 2000-02-24 2001-02-23 Novel antibody with specificity for colon cancer
US10/182,132 US7425623B2 (en) 2000-02-24 2001-02-23 Antibody with specificity for colon cancer
RU2002125386/15A RU2268068C2 (ru) 2000-02-24 2001-02-23 Новое антитело со специфичностью к злокачественной опухоли толстой кишки
CN01805577A CN1406136A (zh) 2000-02-24 2001-02-23 对结肠癌具有特异性的新抗体
EEP200200473A EE200200473A (et) 2000-02-24 2001-02-23 Uudne jämesoolevähi-spetsiifiline antikeha
EP01908551A EP1257291A1 (en) 2000-02-24 2001-02-23 Novel antibody with specificity for colon cancer
MXPA02008315A MXPA02008315A (es) 2000-02-24 2001-02-23 Anticuerpo novedoso con especifidad para cancer de color.
SK1198-2002A SK11982002A3 (sk) 2000-02-24 2001-02-23 Nová protilátka so špecificitou pre rakovinu hrubého čreva
JP2001561350A JP2003523213A (ja) 2000-02-24 2001-02-23 結腸癌に対して特異性を有する新規抗体
ZA200206039A ZA200206039B (en) 2000-02-24 2002-07-29 Novel antibody with specificity for colon cancer.
NO20023670A NO20023670L (no) 2000-02-24 2002-08-02 Antistoff med spesifisitet for colonkreft
HK03104939.3A HK1052648A1 (zh) 2000-02-24 2003-07-09 對結腸癌具有特異性的新抗體

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0000597A SE0000597D0 (sv) 2000-02-24 2000-02-24 Novel antibody

Publications (1)

Publication Number Publication Date
SE0000597D0 true SE0000597D0 (sv) 2000-02-24

Family

ID=20278567

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0000597A SE0000597D0 (sv) 2000-02-24 2000-02-24 Novel antibody

Country Status (22)

Country Link
US (1) US7425623B2 (sk)
EP (1) EP1257291A1 (sk)
JP (1) JP2003523213A (sk)
KR (1) KR20020079888A (sk)
CN (1) CN1406136A (sk)
AU (1) AU775876B2 (sk)
BR (1) BR0108609A (sk)
CA (1) CA2400661A1 (sk)
EE (1) EE200200473A (sk)
HK (1) HK1052648A1 (sk)
HU (1) HUP0300007A3 (sk)
IL (1) IL151325A0 (sk)
MX (1) MXPA02008315A (sk)
NO (1) NO20023670L (sk)
NZ (1) NZ520523A (sk)
PL (1) PL356386A1 (sk)
RU (1) RU2268068C2 (sk)
SE (1) SE0000597D0 (sk)
SK (1) SK11982002A3 (sk)
WO (1) WO2001062286A1 (sk)
YU (1) YU63702A (sk)
ZA (1) ZA200206039B (sk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450692A1 (en) * 2001-06-12 2003-01-30 Kyogo Itoh Tumor antigen
US20030206916A1 (en) 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
CN1303105C (zh) * 2003-12-08 2007-03-07 陈志南 抗人大肠癌单克隆抗体CAb—2轻、重链可变区基因及其应用
EP2044120B1 (en) * 2006-06-07 2019-01-30 BioAlliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
EP2048241B1 (en) * 2007-10-08 2012-07-25 Sividon Diagnostics GmbH Method employing GAPDH as molecular markers for cancer prognosis
RU2528738C2 (ru) * 2007-12-18 2014-09-20 Биоэллаенс К.В. Антитела, узнающие углеводсодержащий эпитоп на cd43 и сеа, экспрессируемых на раковых клетках и способы их применения
CN104698168A (zh) * 2008-09-01 2015-06-10 国立大学法人名古屋大学 抗癌剂作用增强剂及其应用、以及癌患者预后推定用生物标记物及其应用
FR2945952B1 (fr) * 2009-05-27 2013-10-04 Univ Claude Bernard Lyon Anticorps anti-ck8 pour utilisation comme medicament.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798257A (en) * 1990-07-09 1998-08-25 Research Corporation Technologies, Inc. Nucleic acid encoding human MTS-1 protein
US5994088A (en) * 1991-03-08 1999-11-30 Board Of Trustees Of The University Of Illinois Methods and reagents for preparing and using immunological agents specific for P-glycoprotein
IL106610A0 (en) * 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
US5972643A (en) * 1994-06-17 1999-10-26 Fred Hutchinson Cancer Research Center Isolated polynucleotide molecules encoding CTCF, a CCCTC-binding factor
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
CA2241564C (en) * 1996-01-08 2013-09-03 Genentech, Inc. Wsx receptor and ligands
WO1998003411A1 (fr) 1996-07-18 1998-01-29 Montania Bouchon avec recipient auxiliaire et procede de realisation
DE69718341T2 (de) * 1996-10-08 2003-10-30 Bisys B V U Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül
SE9700291D0 (sv) * 1997-01-31 1997-01-31 Pharmacia & Upjohn Ab Selection method and prodcts resulting therefrom
ES2246069T3 (es) * 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
WO1999010485A1 (en) * 1997-08-29 1999-03-04 Selective Genetics, Inc. Methods using phage display for selecting internalizing ligands for gene delivery
DE19739525A1 (de) * 1997-09-09 1999-09-30 Heinrich Abbrederis Die Vorrichtung T.C.Reinigungskopf ermöglicht die Reinigung, Schmierung und Konservierung von Ketten im eingebauten und ausgebauten Zustand unter minimalen Platzverhältnissen
CA2253633A1 (en) * 1997-12-03 1999-06-03 Boehringer Mannheim Corporation Complex specific antibodies, method of preparation and uses thereof
AU770952B2 (en) * 1999-03-01 2004-03-11 Genentech Inc. Antibodies for cancer therapy and diagnosis

Also Published As

Publication number Publication date
JP2003523213A (ja) 2003-08-05
BR0108609A (pt) 2002-11-19
WO2001062286A1 (en) 2001-08-30
AU3629401A (en) 2001-09-03
EP1257291A1 (en) 2002-11-20
YU63702A (sh) 2006-01-16
MXPA02008315A (es) 2002-12-09
CA2400661A1 (en) 2001-08-30
RU2002125386A (ru) 2004-03-20
IL151325A0 (en) 2003-04-10
NO20023670L (no) 2002-08-23
NO20023670D0 (no) 2002-08-02
CN1406136A (zh) 2003-03-26
HUP0300007A2 (en) 2003-05-28
AU775876B2 (en) 2004-08-19
ZA200206039B (en) 2003-07-29
SK11982002A3 (sk) 2003-03-04
NZ520523A (en) 2004-08-27
RU2268068C2 (ru) 2006-01-20
EE200200473A (et) 2004-02-16
US20030176661A1 (en) 2003-09-18
HK1052648A1 (zh) 2003-09-26
KR20020079888A (ko) 2002-10-19
PL356386A1 (en) 2004-06-28
HUP0300007A3 (en) 2005-11-28
US7425623B2 (en) 2008-09-16

Similar Documents

Publication Publication Date Title
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
MXPA05010830A (es) Metodos de tratamiento que usan agentes de enlace especificos de angiopoyetina-2 humana.
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
UA109633C2 (uk) Антитіло людини проти тканинного фактора
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
UY26807A1 (es) Anticuerpos de especificidad doble y métodos para la elaboración y el uso de los mismos
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
NO20055209D0 (no) Peptabody for cancerbehandling
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
ATE330967T1 (de) An her2 bindende peptidverbindungen
TW200604208A (en) Antibodies to angiogenesis inhibiting domains of CD148
MX2007006355A (es) Epitopes antigenos de interleucina-21, anticuerpos relacionados y su uso en el campo medico.
MX2009003039A (es) Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.
DK1526840T3 (da) Nanopartikler til DNA administration til et målorgan
WO2005054295A8 (en) Therapeutic and diagnostic anti-hsp 70 antibodies
EA201690004A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
SE0000597D0 (sv) Novel antibody
WO2002053700A3 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
CY1113424T1 (el) Μεθοδος αντιμετωπισης του καρκινου ή/και παθησεις με κυτταρικη υπερπλασια και παραγοντες που στοχευουν τον αναβολισμο υαλουρονανης για τον ιδιο σκοπο
WO2008137733A3 (en) Micellar structures, methods of making micellar structures, methods of imaging, and methods of delivering agents
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
MXPA02011563A (es) Composicionesy metodos para la terapia y diagnostico de cancer de seno.
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
FR2804027B1 (fr) Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers